Hims & Hers Health is building a large consumer health platform, but recent growth and earnings pressure make the stock a Hold. International expansion and branded GLP-1 access could reaccelerate results, yet valuation already reflects much of the upside.
Hims & Hers Health (HIMS) has built a sizable consumer health platform with 2.6 million subscribers, a broadening specialty mix, recurring relationships, and a growing technology layer. The investment case rests on the company converting its weight-loss pivot, international expansion, and data infrastructure into faster growth and stronger margins. The immediate financial record is less comfortable: Q1 2026 revenue grew only 4% year over year to $608.1M, adjusted EBITDA fell to $44.3M, and GAAP net income swung to a $92.1M loss.
At a quoted price of $31.81, HIMS is priced as a growth company even though its trailing EPS is negative, its forward P/E is 58.8x, and its PEG ratio is 2.2. Management is targeting at least $6.5B of revenue and $1.3B of adjusted EBITDA by 2030, while analyst estimates point to $3.5B of revenue and $0.47 of EPS in 2027. Those targets support a meaningful long-term opportunity, but the stock needs renewed execution before it earns a premium valuation.
The balanced medium-term stance is Hold, with an estimated fair value of $30. The company has real assets in brand, scale, customer data, and clinical workflow. It also carries regulatory exposure, elevated leverage, margin pressure, and a recent earnings setback. HIMS is a promising platform, but promise is not the same as proof, and the market has already paid for much of the promise.
Hims & Hers Health (HIMS) operates a consumer-first health and wellness platform that connects customers with licensed healthcare professionals through websites and mobile applications. The company supports medical consultations, prescriptions, post-consultation services, laboratory testing, product fulfillment, and recurring treatment relationships.
Its categories include sexual health, hair care, skincare, weight loss, hormone health, mental health, menopause, and laboratory testing. HIMS operates in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, and Spain, with additional international reach through acquisitions and planned expansion.
The company generated $2.35B of revenue in 2025, compared with $1.48B in 2024. Operating income reached $105.6M and net income reached $128.4M in 2025. HIMS had 2,442 employees and is led by co-founder, chairman, and chief executive Andrew Dudum.
HIMS reports its business geographically rather than through a detailed category segment structure. The United States generated $529.9M of Q1 2026 revenue, down 8% year over year. Rest-of-world revenue reached $78.2M, up 969% year over year. That international increase was driven by the ZAVA and Livewell businesses and made international operations a material contributor to consolidated growth.
The geographic mix highlights both the opportunity and the risk. International expansion adds markets, partners, and customer data, but it also introduces local prescribing rules, pharmacy requirements, currency exposure, and integration work. Management expects the planned Eucalyptus acquisition to extend its consumer health position across Australia, the United Kingdom, Germany, Japan, and Canada.
Weight loss is the leading strategic growth engine. HIMS shifted its U.S. approach in March 2026 by discontinuing advertising for compounded products and prioritizing branded GLP-1 medications. The move created $33M of restructuring costs, including approximately $28M tied to supply-chain write-downs, but it also expands access to branded products and reduces reliance on a more exposed compounding model.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The flagship product is not one medication. It is the HIMS care pathway, which combines consumer acquisition, digital intake, licensed providers, prescriptions, pharmacy fulfillment, coaching, and follow-up. Weight loss now gives that pathway its widest potential funnel. Management estimates that more than 100 million U.S. adults are struggling with weight, creating a large customer pool for branded GLP-1 products and adjacent services.
HIMS fulfilled more than 125,000 shipments of Novo Nordisk (NVO) Wegovy products within six weeks of introducing direct access to those products. Management also said the company was on track to add more than 100,000 weight-loss subscribers per month, with nearly 90% of those users downloading the application and the average subscriber interacting with a provider three times during the first month.
The testosterone offering demonstrates the broader product strategy. It serves tens of thousands of men, uses at-home blood testing, and connects treatment changes to follow-up results. Management reported that 95% of HIMS customers using testosterone support saw an increase in testosterone levels within two months. That result supports the platform's personalized-care narrative, although it remains a company-reported operating metric rather than a substitute for long-term retention and margin evidence.
HIMS is investing in an integrated technology stack rather than treating telehealth as a simple video-visit product. Management described a no-code commercial engine, configurable clinical workflows, modernized mobile and messaging tools, and a more complete view of each customer's health journey. These tools are designed to support faster launches across conditions and geographies.
The company has nearly 40 members in its artificial intelligence organization. Its provider-side AI copilot drafts contextual responses for care coaches, while human care coaches review those responses. HIMS also launched Labs AI to explain biomarker results in a customer's clinical context and plans an AI weight-loss companion that can prompt customer engagement and clinician escalation.
The strongest potential advantage is the closed-loop data model. HIMS links intake, diagnosis, treatment, provider decisions, follow-up, side effects, and outcomes in one operating environment. Tens of millions of annual customer touch points create a large stream of clinician-reviewed interactions. If the company converts those interactions into better retention and lower service costs, the data layer can become more valuable than the marketing brand alone.
HIMS combines digital customer acquisition with provider operations, fulfillment, laboratory services, and increasingly verticalized infrastructure. The company invested in a U.S.-based peptide facility last year and completed the acquisition of YourBio in Q1 2026. YourBio provides technology for painless at-home blood collection, supporting the company's laboratory and proactive-care ambitions.
The weight-loss pivot exposed the cost of operating a specialized supply chain. HIMS wrote down approximately $28M of compounded GLP-1 supply-chain assets in Q1 after shifting toward branded medications. This episode shows that verticalization can improve control and efficiency, but it can also create inventory and asset-obsolescence risk when regulation or product strategy changes.
Marketing represented 36% of Q1 revenue, improving by three percentage points year over year and quarter over quarter. Management attributed the improvement to stronger retention, increased cross-selling, organic platform activity, and lower-cost acquisition channels. Q1 operating cash flow was $89.4M and free cash flow was $53.0M, giving the company room to fund technology and operational investments while it works through the transition.
HIMS operates at the intersection of consumer health, telehealth, specialty pharmacy, laboratory testing, and digital wellness. The global hospital services market was estimated at $4.83T in 2025 and is projected to reach $6.03T by 2030, a 4.5% compound annual growth rate. The global home healthcare market was estimated at $309.9B in 2025 and is projected to reach $473.8B by 2030, an 8.9% compound annual growth rate.
Those broad markets are not direct revenue pools for HIMS, but they show the direction of care delivery. Home-based services, digital engagement, and lower-friction access are gaining importance as healthcare systems manage chronic conditions, staffing pressure, and rising consumer demand for convenience.
The company's own 2030 target of at least $6.5B in revenue implies a substantial expansion from $2.35B in 2025. Reaching that target requires more than adding weight-loss prescriptions. It requires successful specialty launches, international execution, sustained subscriber retention, and the conversion of technology investment into operating leverage.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
HIMS served 2.584 million subscribers at the end of Q1 2026, up 9% year over year from 2.366 million. Average monthly revenue per subscriber was $80, down 6% year over year from $85. The combination shows that the platform is adding customers while monetization per customer is under pressure.
The customer base spans men and women seeking discreet, convenient care for sexual health, hair loss, skincare, weight management, hormone health, menopause, mental health, and wellness. Weight loss can serve as a broad entry point, while cross-selling gives HIMS a path to increase customer lifetime value through multiple specialties.
Early weight-loss engagement is encouraging. Nearly 90% of new users downloaded the HIMS application, and the average subscriber interacted with a provider three times during the first month. High early engagement can support retention, but the investment case still depends on those customers remaining active after the initial treatment decision.
HIMS competes with Ro, Thirty Madison, Noom, GoodRx (GDRX), Teladoc Health (TDOC), traditional providers, pharmacies, retailers, pharmaceutical companies, and niche condition-specific platforms. The company's 2025 filing describes direct-to-consumer healthcare competition as fragmented, but fragmentation does not remove pressure from larger companies with stronger balance sheets or wider distribution.
Teladoc (TDOC) reported 17.1 million telehealth visits in 2025 and access to approximately 102 million U.S. members at year-end. That scale is largely tied to employer and health-plan relationships, while HIMS is more consumer-facing and subscription-led. The comparison is useful because it shows that HIMS has a distinct model, not because the businesses have identical revenue economics.
HIMS differentiates itself through brand, specialty breadth, recurring subscriptions, provider access, fulfillment, and customer-level data. Its disadvantage is that many of those features can be copied individually. The moat becomes stronger only if the integrated experience produces better retention, lower acquisition costs, and more efficient care than competitors can match.
Regulation is the defining macro risk for HIMS. Telehealth, prescribing, pharmacy operations, compounded medicines, privacy, artificial intelligence, and consumer protection all sit inside changing federal and state frameworks. In March 2026, HIMS shifted its weight-loss strategy toward branded GLP-1 products after discontinuing advertising for compounded products, demonstrating how policy can alter product economics quickly.
The Federal Trade Commission filed a lawsuit against HIMS on July 29, 2026. HIMS said it would vigorously defend itself. The case creates legal expense and reputational exposure at a time when the company is already spending on technology, international growth, and supply-chain restructuring.
International growth adds another layer of operating complexity. HIMS serves customers across North America and Europe and plans to expand through Eucalyptus across Australia, the United Kingdom, Germany, Japan, and Canada. Different prescribing standards, data rules, pharmacy systems, and reimbursement structures can slow integration even when customer demand is strong.
Technology policy also matters. CMS interoperability and prior-authorization rules include compliance dates beginning January 1, 2026 and January 1, 2027 for key requirements. Those rules can support digital healthcare adoption, but they also raise the standard for data governance and clinical workflow compliance.
Cash and marketable securities totaled $1.0B against $1.1B of total debt, leaving HIMS with a manageable but not especially conservative leverage profile.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q1 2026 revenue rose just 4% to $608.1M while adjusted EBITDA fell to $44.3M and GAAP net income swung to a $92.1M loss.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management is aiming for at least $6.5B of revenue and $1.3B of adjusted EBITDA by 2030, while analysts are looking for $3.5B of revenue and $0.47 of EPS in 2027.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At $31.81, HIMS trades at 58.8x forward earnings and a 2.2 PEG ratio, a premium that assumes execution improves quickly.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report sets a Hold fair value of $30, with upside tied to stronger weight-loss execution and international scale.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Hims & Hers Health (HIMS) has moved beyond a narrow telehealth proposition. It now operates a multi-specialty consumer health platform with 2.6 million subscribers, international operations, branded GLP-1 access, laboratory services, and an expanding AI infrastructure. The 2025 results show that the model can generate positive operating income, net income, and cash flow at scale.
The near-term reset matters just as much. Q1 2026 produced only 4% revenue growth, a $92.1M net loss, lower adjusted EBITDA, and a $33M restructuring charge. Debt is materially higher than in prior years, the FTC lawsuit adds pressure, and the stock trades at a premium multiple despite negative trailing EPS.
The investment case improves if branded weight-loss products lift subscriber growth, international revenue continues to scale, and technology reduces the cost to serve customers. Those are specific operating drivers, not abstract optimism. Until the financial statements show that the drivers are working together, the disciplined position is Hold with an estimated fair value of $30.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Hims & Hers Health, Inc. (HIMS) gained despite an EPS miss, as revenue beat estimates and growth momentum stayed intact. This deep-dive examines the mixed print, profitability pressure, Wegovy demand, analyst sentiment, and whether the stock’s gains are supported by fundamentals.
Hims & Hers Health, Inc. (HIMS) drops 5.5% as the company reports earnings misses, pressuring shares in early trading and weighing on investor sentiment.
Intuitive Surgical, Inc. (ISRG) drops after investors reassess its post-earnings growth outlook. Despite strong Q2 results, slower procedure growth, tariff pressure, and a premium valuation are weighing on the stock.